CUE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cue Biopharma Inc (CUE) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently in a bearish trend with no strong positive catalysts, and the financial performance shows mixed results with significant revenue growth but a sharp decline in net income and EPS. Additionally, there are no recent trading signals or influential activity to suggest an immediate entry point.
The technical indicators show a bearish trend. The MACD is negative and expanding downward, the RSI is neutral at 32.071, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 0.244), with resistance levels at R1: 0.308 and R2: 0.327.
The company achieved a significant revenue increase of 1292.26% YoY in Q4 2025, and gross margin remains at 100%.
The net income dropped by -116.69% YoY, and EPS declined by -107.69% YoY. There is no recent news, no congress trading data, and no significant hedge fund or insider activity. The stock has a 50% chance of declining in the next week (-2.93%).
In Q4 2025, revenue increased significantly to $21,942,000 (up 1292.26% YoY), but net income dropped to $1,585,000 (down -116.69% YoY), and EPS fell to 0.01 (down -107.69% YoY). Gross margin remains at 100%.
No recent analyst ratings or price target changes are available for Cue Biopharma Inc.
